Hoffmann-La Roche: Arthritis, Juvenile trials

The registry lists 17 Arthritis, Juvenile studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 7 have results posted.

Phase 1 4Phase 3 10Phase 4 2No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)CompletedNCT01904279Phase 1Results posted
• A Study of Decreased Dose Frequency in Participants With Systemic Juvenile Arthritis Who Experience Laboratory Abnormalities During Treatment With RoActemra/Actemra (Tocilizumab)CompletedNCT01734382Phase 4Results posted
• A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis From France Who Completed WA19977 Core StudyCompletedNCT01673919Phase 3Results posted
• A Long-Term Extension Study of RoActemra/Actemra (Tocilizumab) in Patients With Juvenile Idiopathic Arthritis Who Completed WA19977 Core StudyCompletedNCT01667471Phase 3Results posted
• An Extension Study to WA19977 in Patients With Active Polyarticular-Course Juvenile Idiopathic ArthritisTerminatedNCT01575769Phase 3Results posted
• A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic ArthritisCompletedNCT00988221Phase 3Results posted
• A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)CompletedNCT00642460Phase 3Results posted
• A Study of Tocilizumab in Chinese Participants With Systemic Juvenile Idiopathic Arthritis (sJIA)CompletedNCT03301883Phase 4
• Retrospective Analysis of Pulmonary Arterial Hypertension (PAH) and Related Complications in Juvenile Idiopathic Arthritis (JIA) Participants Treated With Biologic and Non-biologic Disease-modifying Anti-rheumatic Drugs (DMARDs)CompletedNCT02784808
• Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic ArthritisCompletedNCT02165345Phase 1
• A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic ArthritisCompletedNCT01904292Phase 1
• An Extension Long-Term Study of RoActemra/Actemra (Tocilizumab) in Patients With Polyarticular Juvenile Idiopathic Arthritis Who Completed The WA19977 StudyCompletedNCT01727986Phase 3
• A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)CompletedNCT01455701Phase 1
• Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)CompletedNCT00144664Phase 3
• Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)CompletedNCT00144625Phase 3
• Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)CompletedNCT00144612Phase 3
• Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)CompletedNCT00144599Phase 3